ENGLEWOOD, Colo., July 10, 2019 /PRNewswire/ -- Ampio
Pharmaceuticals, Inc. (NYSE American: AMPE), a development stage
biopharmaceutical company focused on the discovery and development
of a novel therapy aimed at treating common inflammatory conditions
for which there are limited treatment options, today announced
that Dan Stokely has been appointed
as Chief Financial Officer.
Michael Macaluso, Ampio CEO,
noted, "As we are already dosing patients in
our pivotal Phase III trial of Ampion, as a
biological treatment for adults with pain due to severe
osteoarthritis of the knee (OAK), we sought a
seasoned CFO with the experience and skills to advise us as we
continue to move toward a future commercialization of Ampion."
Dan Stokely has more than 30
years of experience in finance and accounting and is a Certified
Public Accountant. Dan began his career at Deloitte & Touche
and since that time, he has spent the majority of his career in
positions of financial leadership within both publicly traded and
privately-held pharmaceutical companies. Most recently, since 2012,
Dan served as Executive Vice President and Chief Financial Officer
of Sentynl Therapeutics, a privately-held specialty pharmaceutical
company focused on in-licensing, acquisition, marketing and
distribution of development stage and commercially marketed
prescription products, which was sold to Cadila Healthcare Ltd. in
January 2017. From 2004 to 2012, Dan
served as Vice President of Finance and Chief Accounting Officer of
Victory Pharma, a privately-held specialty pharmaceutical company
focused on in-licensing, internal product development, marketing
and distribution of pain specialty products, which was sold to
Shionogi, Inc., a Japanese pharmaceutical company, in
2011. From 2001 to 2004, Dan served as the Corporate
Controller and Chief Accounting Officer for Wireless Facilities,
Inc. (currently Kratos Defense & Security Solutions), a
publicly traded, global provider of communications and security
services for the wireless communications industry. From 1994
to 2001, Dan served as Corporate Controller of Dura
Pharmaceuticals, a publicly traded pharmaceutical company that was
sold to Elan Pharmaceuticals in late 2000. Dan has a
bachelor's degree in accounting from San Diego
State University.
About Osteoarthritis
Osteoarthritis (OA) is an
incurable and progressive disorder of the joints involving
degradation of the intra-articular cartilage, joint lining,
ligaments, and bone. Certain risk factors in conjunction with
natural wear and tear lead to the breakdown of cartilage. OA is
caused by inflammation of the soft tissue and bony structures of
the joint, which worsens over time and leads to progressive
thinning of articular cartilage. Other symptoms include narrowing
of the joint space, synovial membrane thickening, osteophyte
formation and increased density of subchondral bone.
About Ampio Pharmaceuticals
Ampio Pharmaceuticals, Inc. is a development stage
biopharmaceutical company primarily focused on the development of
Ampion, our product candidate, to treat prevalent inflammatory
conditions for which there are limited treatment options.
Forward-Looking Statements
Ampio's statements in this press release that are not historical
fact, and that relate to future plans or events, are
forward-looking statements within the meaning of the Private
Securities Litigation Reform Act of 1995. Forward-looking
statements can be identified by the use of words such as "believe,"
"expect," "plan," "anticipate," and similar expressions. These
forward-looking statements include statements regarding Ampio's
expectations with respect to Ampion™ and its classification,
as well as those associated with regulatory approvals and other FDA
decisions, the Biological License Application (BLA) , the ability
of Ampio to enter into partnering arrangements, clinical
trials and decisions and changes in business conditions and similar
events, all of which are inherently subject to various risks and
uncertainties. The risks and uncertainties involved include
those detailed from time to time in Ampio's filings with the
Securities and Exchange Commission, including without limitation,
under Ampio's Annual Report on Form 10-K and other documents filed
with the Securities and Exchange Commission. Ampio undertakes no
obligation to revise or update these forward-looking statements,
whether as a result of new information, future events or
otherwise.
Company Contact
Phone: (720) 437-6500
info@ampiopharma.com
View original content to download
multimedia:http://www.prnewswire.com/news-releases/ampio-appoints-dan-stokely-as-the-companys-new-chief-financial-officer-300882236.html
SOURCE Ampio Pharmaceuticals, Inc.